Evotec SE announced today that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb. The collaboration expands the portfolio by two additional drug discovery projects and has designated a target-based programme for further development, triggering payments in total of US$ 26 m to Evotec.
